Cantor Fitzgerald upgraded Cubist Pharmaceuticals (NASDAQ: CBST) from Sell to Hold and raised the price target from $37.00 to $38.00. Cantor Fitzgerald commented, "We believe the company is facing several "investment" years that are likely to adversely impact the bottom line and the stock should therefore only move upwards on evidence of stronger